The pharmaceutical industry has had a rough go of it lately. Between negative headlines (with the recent Mylan EpiPen controversy only the latest controversy), congressional inquiries and calls from insurers and the medical community to defend the price of medications, today's value-focused healthcare landscape presents an unprecedented set of challenges for the sector.
Drug companies, who are spending $90 million to stop Proposition 61, will continue to overcharge Californians until we pass Prop 61 to stop their price gouging.
As part of the settlement, Mylan won't have to acknowledge any wrongdoing.
The soaring cost of EpiPens is the latest in a long run of wildly increased costs of prescription drugs that are unaffordable to many, such as Turing's Daraprim for toxoplasmosis (5,000 percent overnight price increase) and Gilead's Sovaldi for hepatitis C ($84,000 for a 12-week treatment).
“They raised the prices ... to get filthy rich at the expense of our constituents,” Rep. Elijah Cummings (D-Md.) said.
Rep. John Mica Asks Mylan CEO What Her Salary Was Last Year
You are an important part of this confusing and frustrating puzzle.
Jatana Jackson of Montclair, Virginia, filled the prescriptions just like she does every August. Due to severe allergies
The EpiPen, a pre-filled automated syringe used to treat serious allergic reactions, is the latest example of what happens
The FDA is taking a second look at this new device.